| Literature DB >> 26421839 |
Tauqeer Hussain Mallhi1, Amer Hayat Khan1, Azreen Syazril Adnan2, Azmi Sarriff3, Yusra Habib Khan1, Fauziah Jummaat4.
Abstract
BACKGROUND: Dengue induced acute kidney injury (AKI) imposes heavy burden of illness in terms of morbidity and mortality. A retrospective study was conducted to investigate incidence, characteristics, risk factors and clinical outcomes of AKI among dengue patients.Entities:
Mesh:
Year: 2015 PMID: 26421839 PMCID: PMC4589349 DOI: 10.1371/journal.pone.0138465
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study Methodology Flow Diagram.
Comparison of patients with DVI with and without AKI.
| Parameters | Overall patients N = 667 | AKI group N = 95 | Non-AKI group N = 572 |
|
|---|---|---|---|---|
|
| 0.008 | |||
| Adults (12–60 years) | 639 (95.8%) | 86 (90.5%) | 553 (96.7%) | |
| Elders (> 60 years) | 28 (4.2%) | 9 (9.5%) | 19 (3.3%) | |
|
| <0.001 | |||
| Male, n (%) | 378 (56.7%) | 71 (74.3%) | 307 (53.7%) | |
| Female, n (%) | 289 (43.3%) | 24 (25.7%) | 265 (46.3%) | |
|
| . | 0.422 | ||
| Urban | 403 (60.4%) | 54 (43.2%) | 349 (61%) | |
| Rural | 264 (39.6) | 41 (56.8%) | 223 (39%) | |
|
| <0.001 | |||
| DF, n (%) | 588 (88.6%) | 58 (61%) | 530 (96.2%) | <0.001 |
| DHF, n (%) | 74 (10.6%) | 34 (35.8%) | 40 (7%) | <0.001 |
| DSS, n (%) | 5 (0.7%) | 3 (3.16%) | 2 (0.35%) | 0.005 |
| Presence of warning signs, n (%) | 271 (40.6%) | 49 (51.6%) | 222 (38.8%) | 0.020 |
|
| 0.003 | |||
| Primary, n (%) | 594 (89.1%) | 76 (80%) | 518 (90.5%) | |
| Secondary, n (%) | 73 (10.9%) | 19 (20%) | 54 (9.5%) | |
|
| 119 (17.8%) | 34 (35.8%) | 85 (14.9%) | <0.001 |
| Diabetes mellitus, n (%) | 36 (5.4%) | 21 (22.1%) | 15 (2.6%) | <0.001 |
| Hypertension, n (%) | 35 (5.2%) | 15 (15.8%) | 20(3.5%) | <0.001 |
| CKD, n (%) | 33 (4.9%) | 7 (7.4%) | 26 (4.5%) | 0.245 |
| IHD, n (%) | 25 (3.7%) | 13 (13.7%) | 12 (2.1%) | <0.001 |
| CHF, n (%) | 2 (0.3%) | 0 (0%) | 2 (0.4%) | 0.999 |
| HPL, n (%) | 8 (1.2%) | 4 (1.05%) | 4 (0.7%) | 0.01 |
| Temperature > 38 C° | 220 (33%) | 31 (32.6%) | 189 (33%) | 0.706 |
| Co-infection, n (%) | 55 (8.2%) | 8 (8.4%) | 47 (8.25%) | 0.947 |
| Hospitalization > 3 days, n (%) | 338 (49.2%) | 62 (65.3%) | 276 (48.3%) | 0.002 |
| Use of nephrotoxic drugs, n (%) | 112 (16.8%) | 50 (52.6%) | 62 (10.8%) | <0.001 |
| Need of blood transfusion, n (%) | 39 (5.8%) | 7 (7.4%) | 32 (5.6%) | 0.496 |
| Hypokalemia, n (%) | 169 (25.3%) | 20 (21%) | 139 (24.3%) | 0.309 |
| Hyponatremia, n (%) | 258 (38.7%) | 43 (45.3%) | 215 (37.6%) | 0.175 |
| Oliguria, n (%) | 295 (44.2%) | 48 (50.5%) | 247 (43.2%) | 0.186 |
| Thrombocytopenia, n (%) | 394 (59.1%) | 62 (65.3%) | 332 (58%) | 0.217 |
| Transaminitis, n (%) | 360 (54%) | 63 (66.3%) | 297 (51.9%) | 0.005 |
| Respiratory failure, n (%) | 11 (1.6%) | 2 (2.1%) | 9 (1.6%) | 0.707 |
| Rhabdomyolysis, n (%) | 49 (7.4%) | 34 (35.8%) | 15 (2.62%) | <0.001 |
| Multiple organ dysfunctions, n (%) | 93 (14%) | 82 (86.3%) | 11 (2%) | <0.001 |
| Prolonged PT, n (%) | 229 (33.6%) | 43 (45.3%) | 186 (32.5%) | 0.015 |
| Prolonged aPTT, n (%) | 159 (23.8%) | 20 (21%) | 139 (24.3%) | 0.128 |
| Urinary Sedimentations | ||||
| Proteinuria, n (%) | 88 (13.2%) | 26 (27.4%) | 62 (10.8%) | <0.001 |
| Hematuria, n (%) | 12 (1.8%) | 6 (6.3%) | 6 (1%) | 0.002 |
| Glycosuria, n (%) | 29 (4.3%) | 8 (8.4%) | 21 (3.7%) | 0.041 |
| Urine pus, n (%) | 23 (3.4%) | 9 (9.5%) | 14 (2.4%) | 0.001 |
| Urinary epithelia cells, n (%) | 15 (2.2%) | 8 (8.4%) | 7 (1.2%) | <0.001 |
| Mortality, n (%) | 8 (1.2%) | 8 (8.4%) | 0 (0%) | <0.001 |
Multiple organ dysfunctions is referred as dysfunction of ≥2 organ systems; DF: dengue fever, DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome; CKD: chronic kidney disease, IHD: ischemic heart disease, DM: diabetes mellitus, CHF: congestive heart failure; HPL: hyperlipidemia, PT: prothrombin time, aPTT: activated partial thromboplastin time
*Fisher exact test, student t test or Mann-Whitney U test, where appropriate
**Significant
1Phi coefficient (0.1–0.29)
2Phi coefficient (0.3–0.49)
3Phi coefficient (0.5–1.0)
4Cramer`s V coefficient (0.3–0.49)
Comparison of laboratory characteristics among DVI patients with and without AKI.
| Parameters | Overall patients N = 667 | AKI group N = 95 | Non-AKI group N = 572 |
|
|---|---|---|---|---|
| Age (years, mean ± SD) | 30.68 ± 16.13 | 40.75 ±17.24 | 29.01 ±15.32 | <0.001 |
| Anthropometric Characteristics | ||||
| Weight (kg, mean ± SD) | 56.84 ±17.71 | 66.36 ± 13.2 | 55.62 ±17.86 | <0.001 |
| Height (cm, mean ± SD) | 151.78 ±18.06 | 160.26 ± 16.51 | 150.58 ±17.97. | 0.001 |
| BMI (kg/m2, mean ± SD) | 24..42 ± 6.46 | 25.67 ± 4.06 | 24.24 ± 6.72. | 0.054 |
| Serum creatinine (μmol/L, mean ± SD) | 99.13 ± 58.49 | 175.17 ± 124.35 | 86.50 ± 17.99 | <0.001 |
| BUN (mmol/L, mean ± SD) | 4.44 ± 3.43 | 7.73 ± 7.35 | 3.89 ± 1.63 | <0.001 |
| BUN: Cr ratio | 11.58 ± 6.06 | 12.31 ± 11.18 | 11.46 ± 4.69 | 0.215 |
| Uric acid (μmol/L, mean ± SD) | 296.34 ± 112.18 | 371.34 ± 145.81 | 282.16 ± 98.59 | <0.001 |
| Serum K (mmol/L, mean ± SD) | 3.74 ±.55 | 3.83 ±.59 | 3.73 ± 0.54 | 0.112 |
| Serum Na (mmol/L, mean ± SD) | 135.23 ± 7.12 | 134.95 ± 6.18 | 135.28 ± 7.27 | 0.679 |
| Serum albumin (g/L, mean ± SD) | 40.26 ± 15.35 | 39.05 ± 5.89 | 40.48 ± 16.49 | 0.428 |
| AG ratio | 1.79 ± 4.46 | 1.49 ±.47 | 1.84 ± 4.8 | 0.113 |
| AST (IU/L, mean ± SD) | 152.42 ± 209.75 | 188.68 ± 256.79 | 145.86 ± 199.69 | 0.083 |
| ALT (IU/L, mean ± SD) | 114.36 ± 166.64 | 171.74 ± 236.41 | 104.40 ± 149.43 | 0.015 |
| ALP (IU/L, mean ± SD) | 105.85 ± 71.32 | 110.11 ± 73.02 | 105.11 ± 71.08 | 0.558 |
| Total bilirubin (μmol/L, mean ± SD) | 12.29 ± 18.39 | 14.60 ± 18.64 | 11.86 ± 18.34 | 0.207 |
| Urine specific gravity (mean ± SD) | 1.012 ±.009 | 1.012 ±.011 | 1.013 ±.009 | 0.801 |
| Urinary pH (mean ± SD) | 6.2 ± 1.6 | 6.53 ±.862 | 6.17 ± 1.74 | 0.177 |
| Urine volume (ml/24 hours, mean ± SD) | 988.4 ± 692.5 | 982.37 ± 670.37 | 989.4 ± 696.8 | 0.932 |
| Creatinine kinase (IU/L, mean ± SD) | 234.61 ± 125.2 | 300.4 ± 145.4 | 152.4 ± 89.3 | 0.002 |
| Leucocytes (×109/L, mean ± SD) | 5.15 ± 14.77 | 5.30 ± 4.35 | 5.13 ± 15.83 | 0.918 |
| Erythrocytes (×1012/L, mean ± SD) | 4.92 ± 0.63 | 4.88 ±.51 | 4.92 ± 0.65 | 0.105 |
| Thrombocytes (×109/L, mean ± SD) | 97.59 ± 63.14 | 89.51 ± 48.29 | 98.89 ± 65.15 | 0.196 |
| Hemoglobin (g/dL, mean ± SD) | 14.21 ± 7.97 | 14.38 ± 1.63 | 14.18 ± 8.54 | 0.631 |
| Hematocrit (%/L, mean ± SD) | 40.18 ± 5.09 | 41.49 ± 4.47 | 39.98 ± 5.16 | 0.005 |
| PT (seconds, mean ± SD) | 13.13 ± 1.35 | 15.42 ± 2.84 | 11.84 ± 0.88 | <0.001 |
| aPTT (seconds, mean ± SD) | 44.23 ± 9.01 | 44.74 ± 7.99 | 44.15 ± 9.18 | 0.563 |
| International normalized ratio (INR) | 1.05 ± 0.56 | 1.17 ±.96 | 1.0329 ± 0.44 | 0.227 |
| Length of hospitalization (days, mean ± SD) | 4.87 ± 2.75 | 5.79 ± 3.45 | 4.72 ± 2.58 | 0.005 |
| Period of illness prior to hospitalization (days, mean ± SD) | 4.16 ± 3.28 | 5.89 ± 1.21 | 3.72 ± 2.34 | <0.001 |
*Significant, P value is subjected to difference between AKI and non-AKI patients and calculated by student-t test or Mann-Whitney U test, where appropriate. BMI: body mass index, BUN: blood urea nitrogen; AG: albumin to globulin ratio, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase, PT: Prothrombin time: aPTT: activated partial thromboplastin time
Independent risk factors for AKI by univariate and multivariate analysis.
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| P-value | OR | 95% CI for OR | P-value | OR | 95% CI for OR | |
| Old age | 0.008 | 3.1 | 1.34–6.95 | 0.924 | 1.1 | 0.26–4.15 |
| Male Gender | <0.001 | 8.1 | 4.79–13.52 |
|
|
|
| DHF | <0.001 | 7.4 | 4.37–12.57 |
|
|
|
| Low albumin | <0.531 | 2.1 | 0.90–5.34 | – | – | – |
| Rhabdomyolysis | <0.001 | 20.7 | 10.67–40.15 |
|
|
|
| Multiple organ dysfunction | <0.001 | 33.8 | 19.47–58.76 |
|
|
|
| CKD | 0.245 | 1.7 | 0.71–3.97 | 0.354 | 2.2 | 0.42–11.24 |
| Hypertension | <0.001 | 5.6 | 2.78–11.24 | 0.654 | 0.8 | 0.22–2.60 |
| Diabetes Mellitus | <0.001 | 10.5 | 5.21–21.34 |
|
|
|
| Late hospitalization | 0.009 | 1.8 | 1.16–2.823 |
|
|
|
| Use of nephrotoxic drugs | <0.001 | 9.1 | 5.71–14.79 |
|
|
|
| Elevated ALP | 0.770 | 1.1 | 0.64–1.85 | - | - | - |
Variables with P<0.25 (Low albumin, Elevated ALP) were excluded from multivariate analysis
Odds ratio (OR) and Confidence interval (CI) have been rounded off.
DHF: dengue hemorrhagic fever, ALP: alkaline phosphatase, CKD: chronic kidney disease
*All grades of DHF including 5 cases of DSS
┬ patients admitting to hospital on or after day 5 of onset of symptoms
Fig 2ROC Curve analysis of Multivariate regression model of AKI among dengue patients.
Patient`s outcomes at discharge.
| Outcomes | Overall N = 667 | AKI group N = 95 | Non-AKI group N = 572 |
|
|---|---|---|---|---|
| Fully recovered (without renal and hepatic impairment) | 349 (52.3%) | 0 | 349 (61%) | <0.001 |
| Renal functions at discharge | <0.001 | |||
| Normal renal function | 586 (87.9%) | 49 (51.6%) | 537 (93.9%) | |
| Renal insufficiency with Scr <200 μmol/L | 75 (11.2%) | 40 (42.1%) | 35 (6.1%) | |
| Renal insufficiency with Scr >200 μmol/L | 6 (0.9%) | 6 (6.3%) | 0 | |
| Hepatic function at discharge | 0.017 | |||
| Normal hepatic functions | 437 (65.1%) | 56 (58.9) | 381 (66.6%) | |
| Mild hepatic disturbance | 202 (30.3%) | 40 (42.1%) | 162 (28.3%) | |
| Moderate to severe hepatic disturbance | 38 (5.7%) | 9 (9.5%) | 29 (5.1%) | |
| Need of dialysis | 0 | 0 | 0 | - |
| Need of blood transfusion | 39 (5.8%) | 7 (7.4%) | 32 (5.6%) | 0.495 |
*Pearson Chi-Square
Scr: serum creatinine, μmol/L: micromole per liter